Blog

Laparoscopic Resection Rectopexy Outperforms Delorme’s for Rectal Prolapse

Laparoscopic resection rectopexy significantly reduces recurrence rates in full-thickness rectal prolapse compared to Delorme’s procedure.

  • Recurrence rates within 24 months: 8.2% for laparoscopic resection vs. 42.8% for Delorme’s.
  • Laparoscopic surgery had a median time to recurrence of 17.8 months, compared to 8.2 months for Delorme’s.

Choose laparoscopic resection for better long-term outcomes and improved quality of life for your patients.

  • Overall morbidity was low, with reoperation rates at 0% for laparoscopic resection and 33.3% for Delorme’s.

Journal Article by Herrle F, Sandra-Petrescu F (…) Kienle P et 30 al. in Ann Surg

Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.

read the whole article in Ann Surg

open it in PubMed

Neoadjuvant Therapy Improves Outcomes in Intrahepatic Cholangiocarcinoma

Neoadjuvant chemotherapy followed by surgery significantly improves survival and reduces recurrence in patients with potentially resectable intrahepatic cholangiocarcinoma.

  • Median overall survival was 52.9 months for neoadjuvant therapy versus 37.0 months for upfront surgery.
  • Recurrence risk was lower at 57.7% compared to 65.7%, and the time to relapse extended to 16.5 months from 10.7 months.

This evidence supports considering neoadjuvant chemotherapy as a standard approach for high-risk patients.

  • Five-year survival rates reached 45.7% with neoadjuvant therapy, compared to 32.5% with upfront surgery.

Journal Article by Elemosho A, Chatzipanagiotou OP, Angez M and Pawlik TM in J Gastrointest Surg

Copyright © 2025 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights reserved.

read the whole article in J Gastrointest Surg

open it in PubMed

Gallstone Disease and Lifestyle Factors: A New Approach

Higher lifestyle health scores may reduce gallstone disease risk.

  • A standard deviation increase in Life’s Essential 8 (le8) decreases gallstone odds by 29%.
  • Life’s Crucial 9 (lc9), which includes mental health, reduces odds by 31% and shows better predictive power than le8.

Consider integrating lifestyle assessments into patient evaluations to lower gallstone disease risk.

  • lc9 offers a stronger framework for lifestyle counseling and prevention strategies during surgical decision-making.

Journal Article by Wang J, Le Q (…) Wang H et 2 al. in Int J Surg

Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.

read the whole article in Int J Surg

open it in PubMed

Gastric Cancer Treatment Shift: Prioritizing Patient Outcomes

Gastric cancer with peritoneal metastases is rising, especially in younger patients, highlighting the urgent need for better outcomes.

  • Novel therapies like normothermic intraperitoneal and systemic chemotherapy have shown overall survival benefits.
  • Patient-reported outcomes remain underreported in major trials, with critical insights missed from studies like Dragon-01.

Incorporating tailored patient-reported measures into clinical trials is essential for improving survivors’ quality of life alongside survival rates.

  • Enhanced focus on patient experience will guide effective treatment strategies moving forward.

Review by Burke E in J Gastrointest Cancer

© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

read the whole article in J Gastrointest Cancer

open it in PubMed

Effective Weight Loss Device for Type 2 Diabetes and Obesity

An endoscopically placed bypass liner significantly improves glycemic control and weight loss in patients with poorly controlled type 2 diabetes and obesity.

  • HbA1c reduction at 12 months was -1.10% for the bypass group versus -0.28% for sham (p=0.0004).
  • Patients in the bypass group experienced a 7.7% total weight loss compared to 2.1% in the sham group (p<0.0001).

Consider this device for patients struggling with both diabetes management and obesity; it shows potential for better surgical outcomes and patient quality of life.

  • 28.3% of the bypass group achieved HbA1c ≤ 7% compared to 9.4% in the sham group (p<0.0003).

Journal Article by Thompson CC, Jirapinyo P (…) Schauer P et 12 al. in Ann Surg

Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.

read the whole article in Ann Surg

open it in PubMed

New treatment shows promise for refractory GERD patients

Anti-reflux mucosal ablation significantly benefits patients with reflux-predominant GERD unresponsive to PPI therapy.

  • 71.4% of patients receiving mucosal ablation reported at least a 50% improvement in quality of life after 6 months, compared to just 3.6% in the sham group (p<0.001).
  • Significant reductions in heartburn, regurgitation, and reflux episodes were observed, with 35.7% of patients able to discontinue PPIs.

This technique may change the surgical approach to managing refractory GERD.

  • Improvements in endoscopic findings were noted, further supporting its efficacy.

Journal Article by Chavan D, Koduri KK (…) Reddy ND et 4 al. in Endoscopy

Thieme. All rights reserved.

read the whole article in Endoscopy

open it in PubMed

Endoscopic Submucosal Dissection Effective for Rectal Neoplasms

Endoscopic submucosal dissection (ESD) shows promise for safely resecting rectal neoplasms near the dentate line, improving surgical options.

  • En bloc resection rates reached 93.7% and R0 resection rates were at 85.4% in 255 patients.
  • Overall adverse events occurred in just 8.7%, with manageable complications like bleeding (5.1%).

This technique could replace traditional transanal methods, but careful patient selection and planning are crucial for optimal outcomes.

Journal Article by Sharma NR, Gopakumar H (…) Draganov PV et 32 al. in J Clin Gastroenterol

Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.

read the whole article in J Clin Gastroenterol

open it in PubMed

Emerging Techniques for GERD: Long-Term Efficacy Insights

Novel minimally invasive procedures for gastroesophageal reflux disease show promising outcomes, impacting patient selection and surgical approaches.

  • Esophyx and Linx provide long-lasting symptom relief, with sustained quality of life improvements for chronic GERD patients.
  • Stretta shows clinically significant long-term effects on proton pump inhibitor usage and pH monitoring but has limited follow-up data.

Surgeons should consider patient characteristics, such as hiatal hernias and PPI response, when selecting these procedures.

  • Muse and Refluxstop need better data for clearer clinical roles.

Review by Hansson MR, Tsoposidis A (…) Håkanson B et 4 al. in Scand J Surg

read the whole article in Scand J Surg

open it in PubMed

Predicting Liver Failure After Hepatectomy: Key Early Indicators

Early liver function tests can help surgeons identify patients at risk for post-hepatectomy liver failure (PHLF), improving outcomes.

  • In a study of 445 patients, 8.5% developed PHLF.
  • On postoperative day 3, bilirubin ≥1.8 mg/dl (sensitivity 93.3%) and INR ≥1.18 (sensitivity 80.6%) strongly predicted PHLF.
  • Relying on current guidelines starting at day 5 could delay important interventions.

Early recognition of liver dysfunction could enhance surgical decision-making and patient outcomes.

Journal Article by Abdelhadi S, El-Ahmar M (…) Sandra-Petrescu F et 7 al. in Front Surg

© 2025 Abdelhadi, El-Ahmar, Vedder, Halawa, Orth, Hermann, Mönnichs, Vassilev, Reissfelder and Sandra-Petrescu.

read the whole article in Front Surg

open it in PubMed

Preoperative A1C Screening Critical for Surgery Outcomes

Elevated preoperative hemoglobin A1C is linked to higher postoperative complications in general surgery.

  • 36% of patients had diagnosed diabetes; 6.4% had undiagnosed diabetes with A1C levels indicating the condition.
  • Complications risk increased with A1C levels: from 1.06 for <6.0% to 1.32 for >9.0%.
  • Undiagnosed diabetes led to 24% higher mortality risk and 11% higher risk of medical complications.

Routine A1C screening can help identify high-risk patients and guide individualized glycemic management, improving surgical outcomes.

Journal Article by Schaschinger T, Niederegger T (…) Hundeshagen G et 11 al. in JAMA Surg

read the whole article in JAMA Surg

open it in PubMed